((自动化翻译由路透提供，请见免责声明 ))
10月24日 - ** 药物开发商Monopar Therapeutics的 股价盘前上涨13%，报5.25美元
** 公司与阿斯利康 旗下的Alexion公司签署了 (link) 协议，获得了AZN公司正在测试的治疗威尔逊病的实验性药物的许可，威尔逊病是一种罕见的遗传病，会导致有毒铜含量的积累。
** Monopar 将负责未来的全球开发和药物商业化活动
** 根据交易条款，Monopar 将以现金和 Monopar 股权的形式向 Alexion 支付预付款。
** 截至上一交易日收盘，Monopar 的股价已上涨了两倍多。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.